Key facts
as of Sep 2026- Triveni Bio’s last known valuation is $310.0M (Jun 2025).
- It has raised $231.6M across 2 recorded rounds; the latest was Later Stage VC (Series B) ($115.0M) in Jun 2025.
- Notable investors include Fidelity Management & Research Company, Viking Global Investors, Alexandria Venture Investments, OrbiMed, Goldman Sachs Asset Management — 12 tracked in total.
- 1 institutional filer reports fund marks on Triveni Bio across 6 filings.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Triveni Bio
Recorded secondary trades
No secondary trades in Triveni Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest May 20261 SEC-registered fund reported 6 fair-value marks on Triveni Bio between May 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
2 roundsAbout Triveni Bio
Developer of a clinical-stage biotechnology company designed to create antibody-based therapies targeting immunological and inflammatory diseases. The company offers a genetics-informed antibody discovery and engineering platform, deep insights from human genetic data, and biologics targeting validated disease mechanisms, enabling patients and clinicians dealing with immune and inflammatory disorders access to potentially more effective and precise treatments.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2019
- Employees
- 45
- Website
- triveni.bio/
- Ownership
- Privately Held (backing)